EU/3/07/496: Orphan designation for the treatment of acute lymphoblastic leukaemia


Table of contents


On 22 October 2007, orphan designation (EU/3/07/496) was granted by the European Commission to Only for Children Pharmaceuticals, France, for mercaptopurine (oral liquid) for the treatment of acute lymphoblastic leukaemia.

The sponsorship was transferred to Orbona Pharma Ltd, United Kingdom, in October 2013.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Intended use
Treatment of acute lymphoblastic leukaemia
Orphan designation status
EU designation number
Date of designation
Orbona Pharma Ltd
Old Chambers
93-94 West Street
Surrey GU97EB
United Kingdom
Tel. +44 (0)1252 21 63 27
Fax +44 (0)1252 72 08 24

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating